Editas Medicine, Inc. (EDIT)

NASDAQ: EDIT · IEX Real-Time Price · USD
9.99
+0.10 (1.01%)
Feb 1, 2023, 10:21 AM EST - Market open
1.01%
Market Cap 686.94M
Revenue (ttm) 25.64M
Net Income (ttm) -201.13M
Shares Out 68.76M
EPS (ttm) -2.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 476,768
Open 10.30
Previous Close 9.89
Day's Range 9.78 - 10.30
52-Week Range 7.71 - 21.60
Beta 1.87
Analysts Hold
Price Target 15.75 (+57.66%)
Earnings Date Feb 23, 2023

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pi... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2016
Employees 264
Stock Exchange NASDAQ
Ticker Symbol EDIT
Full Company Profile

Financial Performance

In 2021, EDIT's revenue was $25.54 million, a decrease of -71.85% compared to the previous year's $90.73 million. Losses were -$192.50 million, 66.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for EDIT stock is "Hold." The 12-month stock price forecast is $15.75, which is an increase of 57.66% from the latest price.

Price Target
$15.75
(57.66% upside)
Analyst Consensus: Hold
Stock Forecasts

News

7 CRISPR Stocks With the Best Long-Term Potential

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease...

1 day ago - InvestorPlace

Editas Medicine (EDIT) Crossed Above the 50-Day Moving Average: What That Means for Investors

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

1 day ago - Zacks Investment Research

How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?

The 2023 calendar year has already been rocky for many biotech companies. Just three weeks into the new year, layoffs are already plaguing the industry.

Other symbols: ELEVFATEIPSCJNJYMAB
6 days ago - MarketBeat

Editas Medicine (EDIT) Crossed Above the 20-Day Moving Average: What That Means for Investors

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

6 days ago - Zacks Investment Research

Wall Street Analysts Predict a 72.25% Upside in Editas (EDIT): Here's What You Should Know

The mean of analysts' price targets for Editas (EDIT) points to a 72.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

6 days ago - Zacks Investment Research

Editas (EDIT) Moves Ahead With its Portfolio Reprioritization

Editas (EDIT) enters into a deal with Shoreline Biosciences for licensing Editas proprietary gene editing technologies and cell franchise.

1 week ago - Zacks Investment Research

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas' iNK Cell Franchise and Related Gene Editing Technologies

Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and  a non-exclusive license for...

1 week ago - GlobeNewsWire

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland C...

Other symbols: CRSPGNOM
1 week ago - InvestorPlace

Editas (EDIT) Dips on Portfolio Reprioritization, To Cut Jobs

Editas (EDIT) enters a restructuring and portfolio reprioritization to focus on hemoglobinopathies and in vivo gene editing. The company is to reduce its workforce by almost 20%.

3 weeks ago - Zacks Investment Research

Editas Medicine tumbles more than 7% after announcing job cuts, restructuring

Editas Medicine Inc. [s: edit] is cutting approximately 20% of its workforce. The company reported 1,800 employees as of May 31, according to its annual report.

3 weeks ago - Market Watch

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing

3 weeks ago - GlobeNewsWire

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company's President and CEO Gilmore O'Neill,...

1 month ago - GlobeNewsWire

Editas shares jump 9% on positive news from sickle-cell study

Shares of Editas Medicine Inc. EDIT, -4.10% rallied 9.3% in premarket trading on Tuesday after the company said in a news release that it had positive results from the first two patients enrolled in a...

2 months ago - Market Watch

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

EDIT-301 was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

2 months ago - GlobeNewsWire

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a live webinar on, Tuesday, Decembe...

2 months ago - GlobeNewsWire

Editas (EDIT) Declines More Than 30% in 3 Months: Here's Why

Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.

2 months ago - Zacks Investment Research

Here's Why Editas (EDIT) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Editas (EDIT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revision...

2 months ago - Zacks Investment Research

Editas (EDIT) Pauses Eye Disease Study on EDIT-101, Stock Down

Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.

2 months ago - Zacks Investment Research

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

EDIT-101 demonstrates a favorable safety profile across all dose cohorts

2 months ago - GlobeNewsWire

Editas' (EDIT) Q3 Earnings Beat Estimates, Pipeline in Focus

Editas (EDIT) reports a narrower-than-expected loss for the third quarter of 2022. Focus remains on the lead candidate, EDIT-101, as well as other pipeline candidates.

3 months ago - Zacks Investment Research

Editas Medicine (EDIT) Reports Q3 Loss, Misses Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

Dosed second patient with EDIT-301 in the Phase 1/2 RUBY trial for sickle cell disease

3 months ago - GlobeNewsWire

Wall Street Analysts Believe Editas (EDIT) Could Rally 139%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 138.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positi...

3 months ago - Zacks Investment Research

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that it will host a conference call and webcast on We...

3 months ago - GlobeNewsWire

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

Studies in non-human primates demonstrated nearly 100% gene editing and knockout of endogenous RHO gene and more than 30% replacement protein levels using a dual vector AAV approach

3 months ago - GlobeNewsWire